Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189679 | 0.92 | GAA (0.63) | PIK3CDPIK3CGGAAALDH1A1ALOX15 | |
| SCHEMBL189228 | 0.88 | GAA (0.57) | PIK3CDPIK3CGGAAALDH1A1HSD17B10 | |
| SCHEMBL12653081 | 0.86 | PIK3CG (0.55) | PIK3CDPIK3CG | |
| SCHEMBL188736 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3CGGAA | |
| SCHEMBL12386654 | 0.84 | PIK3CD (0.59) | PIK3CDPIK3CG | |
| SCHEMBL12387586 | 0.83 | PIK3CD (0.57) | PIK3CDPIK3CGMAPT | |
| SCHEMBL188873 | 0.81 | PIK3CG (0.57) | PIK3CDPIK3CGGAA | |
| SCHEMBL188756 | 0.80 | PIK3CG (0.57) | PIK3CDPIK3CGGAAALDH1A1MAPT | |
| SCHEMBL189095 | 0.78 | PIK3CG (0.59) | PIK3CDPIK3CGGAAALDH1A1MAPT | |
| SCHEMBL189069 | 0.78 | PIK3CD (0.56) | PIK3CDPIK3CGGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | EXELIXIS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | PIK3CA, PIK3CB, PIK3CG | PIK3CD 4/4885PIK3CG 3/4885GAA 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.